These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 15388349

  • 1. Synthesis of disaccharides derived from heparin and evaluation of effects on endothelial cell growth and on binding of heparin to FGF-2.
    O'Brien A, Lynch C, O'Boyle KM, Murphy PV.
    Carbohydr Res; 2004 Oct 04; 339(14):2343-54. PubMed ID: 15388349
    [Abstract] [Full Text] [Related]

  • 2. Synthesis of a glucuronic acid and glucose conjugate library and evaluation of effects on endothelial cell growth.
    Pitt N, Duane RM, O'Brien A, Bradley H, Wilson SJ, O'Boyle KM, Murphy PV.
    Carbohydr Res; 2004 Aug 02; 339(11):1873-87. PubMed ID: 15261580
    [Abstract] [Full Text] [Related]

  • 3. Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts.
    Delehedde M, Lyon M, Gallagher JT, Rudland PS, Fernig DG.
    Biochem J; 2002 Aug 15; 366(Pt 1):235-44. PubMed ID: 12000311
    [Abstract] [Full Text] [Related]

  • 4. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation.
    Foxall C, Wei Z, Schaefer ME, Casabonne M, Fugedi P, Peto C, Castellot JJ, Brandley BK.
    J Cell Physiol; 1996 Sep 15; 168(3):657-67. PubMed ID: 8816920
    [Abstract] [Full Text] [Related]

  • 5. Heparin-dependent fibroblast growth factor activities: effects of defined heparin oligosaccharides.
    Zhou FY, Kan M, Owens RT, McKeehan WL, Thompson JA, Linhardt RJ, Höök M.
    Eur J Cell Biol; 1997 May 15; 73(1):71-80. PubMed ID: 9174673
    [Abstract] [Full Text] [Related]

  • 6. The cysteine-free fibroblast growth factor 1 mutant induces heparin-independent proliferation of endothelial cells and smooth muscle cells.
    Xue L, Shireman PK, Hampton B, Burgess WH, Greisler HP.
    J Surg Res; 2000 Aug 15; 92(2):255-60. PubMed ID: 10896831
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate.
    Fairweather JK, Karoli T, Liu L, Bytheway I, Ferro V.
    Carbohydr Res; 2009 Nov 23; 344(17):2394-8. PubMed ID: 19819428
    [Abstract] [Full Text] [Related]

  • 9. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M.
    J Med Chem; 2004 Feb 12; 47(4):838-48. PubMed ID: 14761186
    [Abstract] [Full Text] [Related]

  • 10. Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1.
    Berry D, Shriver Z, Natke B, Kwan CP, Venkataraman G, Sasisekharan R.
    Biochem J; 2003 Jul 01; 373(Pt 1):241-9. PubMed ID: 12659634
    [Abstract] [Full Text] [Related]

  • 11. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.
    Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S, Shridhar V.
    Cancer Res; 2006 Jun 15; 66(12):6025-32. PubMed ID: 16778174
    [Abstract] [Full Text] [Related]

  • 12. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
    Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I.
    J Clin Invest; 1997 Apr 01; 99(7):1565-75. PubMed ID: 9120000
    [Abstract] [Full Text] [Related]

  • 13. Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carbohybrid library.
    Murphy PV, Pitt N, O'Brien A, Enright PM, Dunne A, Wilson SJ, Duane RM, O'Boyle KM.
    Bioorg Med Chem Lett; 2002 Nov 18; 12(22):3287-90. PubMed ID: 12392734
    [Abstract] [Full Text] [Related]

  • 14. VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration.
    Li D, Zhang C, Song F, Lubenec I, Tian Y, Song QH.
    Microvasc Res; 2009 Mar 18; 77(2):134-42. PubMed ID: 18948122
    [Abstract] [Full Text] [Related]

  • 15. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D.
    Arterioscler Thromb Vasc Biol; 2005 Jan 18; 25(1):71-6. PubMed ID: 15514208
    [Abstract] [Full Text] [Related]

  • 16. Prostate cells express two isoforms of fibroblast growth factor receptor 1 with different affinities for fibroblast growth factor-2.
    Roghani M, Moscatelli D.
    Prostate; 2007 Feb 01; 67(2):115-24. PubMed ID: 17143873
    [Abstract] [Full Text] [Related]

  • 17. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans.
    Reis RC, Schuppan D, Barreto AC, Bauer M, Bork JP, Hassler G, Coelho-Sampaio T.
    Biochem Biophys Res Commun; 2005 Aug 05; 333(3):976-83. PubMed ID: 15985216
    [Abstract] [Full Text] [Related]

  • 18. Modulation of FGF-2 binding to chondrocytes from the developing growth plate by perlecan.
    Govindraj P, West L, Smith S, Hassell JR.
    Matrix Biol; 2006 May 05; 25(4):232-9. PubMed ID: 16481152
    [Abstract] [Full Text] [Related]

  • 19. Endothelial and fibroblast cell-derived heparan sulphate bind with differing affinity to basic fibroblast growth factor.
    Pye DA, Kumar S.
    Biochem Biophys Res Commun; 1998 Jul 30; 248(3):889-95. PubMed ID: 9704022
    [Abstract] [Full Text] [Related]

  • 20. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
    Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R, Claesson-Welsh L.
    Cancer Res; 2004 Dec 15; 64(24):9012-7. PubMed ID: 15604266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.